164 related articles for article (PubMed ID: 36453102)
1. Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition.
Bütow M; Testaquadra FJ; Baumeister J; Maié T; Chatain N; Jaquet T; Tillmann S; Crysandt M; Costa IG; Brümmendorf TH; Schemionek M
Haematologica; 2023 Apr; 108(4):1179-1185. PubMed ID: 36453102
[No Abstract] [Full Text] [Related]
2. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.
Smith CC; Shah NP
Clin Cancer Res; 2011 Nov; 17(21):6605-7. PubMed ID: 21948230
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S
Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212
[TBL] [Abstract][Full Text] [Related]
4. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
5. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
6. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
[TBL] [Abstract][Full Text] [Related]
7. The challenges of targeting chronic myeloid leukemia stem cells.
Jiang X; Smith C; Eaves A; Eaves C
Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 2():S71-80. PubMed ID: 17382016
[TBL] [Abstract][Full Text] [Related]
8. Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
Spencer A; Granter N
Exp Hematol; 1999 Sep; 27(9):1397-401. PubMed ID: 10480430
[TBL] [Abstract][Full Text] [Related]
9. Chronic versus acute myelogenous leukemia: a question of self-renewal.
Jamieson CH; Weissman IL; Passegué E
Cancer Cell; 2004 Dec; 6(6):531-3. PubMed ID: 15607956
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia stem cells and developing therapies.
Donato NJ; Peterson LF
Leuk Lymphoma; 2011 Feb; 52 Suppl 1():60-80. PubMed ID: 21299460
[TBL] [Abstract][Full Text] [Related]
11. Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
Ichim CV
Stem Cells Transl Med; 2014 Apr; 3(4):405-15. PubMed ID: 24598782
[TBL] [Abstract][Full Text] [Related]
12. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
[TBL] [Abstract][Full Text] [Related]
13. Targeting chronic myeloid leukemia stem cells.
Kinstrie R; Copland M
Curr Hematol Malig Rep; 2013 Mar; 8(1):14-21. PubMed ID: 23264204
[TBL] [Abstract][Full Text] [Related]
14. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
15. Genetic separation of chronic myeloid leukemia stem cells from normal hematopoietic stem cells at single-cell resolution.
Chen Y; Möbius S; Riege K; Hoffmann S; Hochhaus A; Ernst T; Rudolph KL
Leukemia; 2023 Jul; 37(7):1561-1566. PubMed ID: 37237078
[No Abstract] [Full Text] [Related]
16. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
[TBL] [Abstract][Full Text] [Related]
17. Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?
Soverini S; De Santis S; Monaldi C; Bruno S; Mancini M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209376
[TBL] [Abstract][Full Text] [Related]
18. A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche.
Guarnerio J; Mendez LM; Asada N; Menon AV; Fung J; Berry K; Frenette PS; Ito K; Pandolfi PP
Nat Commun; 2018 Jan; 9(1):66. PubMed ID: 29302031
[TBL] [Abstract][Full Text] [Related]
19. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X
J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755
[TBL] [Abstract][Full Text] [Related]
20. Leukemic colony formation from patients with acute leukemia: evidence of the identity in karyotype of the colonies from patients with cytogenetic abnormalities.
Ishibashi T
Fukushima J Med Sci; 1987 Dec; 33(2):71-83. PubMed ID: 3509037
[No Abstract] [Full Text] [Related]
[Next] [New Search]
